# 輝瑞將獲得 Novavax Matrix-M 佐劑的非獨家使用權，該專有技術旨在增強疫苗的免疫反應。

*biotech · news · 2026-01-21 · USA Herald*

## Key points

- 輝瑞獲得 Novavax Matrix-M 佐劑的非獨家權利，可用於最多兩款疫苗。
- Novavax 將獲得 3,000 萬美元的前期付款及最高 5 億美元的里程碑付款。
- 在現任執行長領導下，投資者及業界對 Novavax Matrix-M 平台的興趣達到最高峰。
- 此輝瑞協議與 Novavax 2024 年與賽諾菲簽訂的 12 億美元授權協議高度相似。

USA Herald – Novavax has landed a major pharmaceutical partnership after signing a new vaccine technology licensing agreement with Pfizer, a move that sent the biotech company’s shares sharply higher and signaled renewed commercial interest in its immune-boosting platform. Under the agreement, Pfizer will gain non-exclusive access to Novavax’s Matrix-M adjuvant, a proprietary technology designed to enhance immune responses in vaccines. The deal allows Pfizer to apply the technology in up to two infectious disease programs, with Pfizer retaining control over development, manufacturing, and commercialization. Novavax will receive an upfront payment of $30 million in the first quarter of 2026 and could earn up to $500 million in additional milestone payments, along with tiered royalties based on future product sales. Investor Focus Returns to Matrix-M Platform The announcement marks a significant moment for Novavax, which has faced mounting investor scrutiny following declining sales of its COVID-19 vaccine as U.S. immunization guidelines tightened. Chief Executive Officer John Jacobs said interest in the Matrix-M platform has surged, noting the company is receiving more partnership inquiries than at any point during his tenure. Industry analysts said the Pfizer deal closely mirrors Novavax’s $1.2 billion licensing agreement with Sanofi signed in 2024, reinforcing the long-term value of the adjuvant technology. “This agreement strengthens Novavax’s strategic position and supports its long-term viability,” analysts at H.C. Wainwright said, adding that additional licensing deals could follow this year.

**Companies:** Pfizer, Novavax
**Countries:** USA

[Read the full story on USA Herald](https://usaherald.com/exclusive-news-data-and-analytics-for-financial-market-professionals-world-business-markets-sustainability-legal-commentary-technology-investigations-more-my-news-novavax-signs-licensing-agre/)

---

Canonical: https://newsio.io/zh-TW/n/d1c4971b-95e6-4f72-aa28-5d6f184f26f9/novavax-matrix-m
Summarized by Newsio from USA Herald. https://newsio.io/how-it-works